MedTrace Logo

Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma

NCT00540644 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2016-06-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study to explore the combination of Revlimid®, oral cyclophosphamide and prednisone (RCP) in patients with newly diagnosed multiple myeloma.

Conditions

Interventions

DRUG

lenalidomide (Revlimid®)

25 mg p.o. daily on days 1-21 of each 28 day cycle

DRUG

Cyclophosphamide

50 mg p.o. BID daily on days 1-21 of each 28 day cycle

DRUG

Prednisone

50 mg p.o. Q.O.D.

Sponsors & Collaborators

  • Celgene

    collaborator INDUSTRY

  • Attaya Suvannasankha

    lead OTHER

Principal Investigators

  • Attaya Suvannasankha, M.D. · Indiana University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2012-12-31
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00540644 on ClinicalTrials.gov